MG-ZG122 / Mabgeek - LARVOL DELTA

Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of MG-ZG122, a long-acting humanized anti-thymic stromal lymphopoietin mAb, in healthy Chinese: a randomized, double-blind, placebo-controlled, dose-escalation, phase I study. (PubMed, Expert Opin Investig Drugs) - P1 | "MG-ZG122 was safe and well-tolerated with favorable PK profiles after a single SC injection in healthy Chinese at doses ranging from 52.5 to 420 mg, providing preliminary evidence for further evaluation. This study was registered with ClinicalTrials.gov, NCT05659927."

Clinical • Journal • P1 data • PK/PD data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • TSLP

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects (clinicaltrials.gov) - P2 | N=160 | Active, not recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=34 | Active, not recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2023 ➔ Mar 2024 | Trial primary completion date: Aug 2023 ➔ Jan 2024

Enrollment closed • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL5

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=34 | Not yet recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL5